BioLife Solutions Competitors

BioLife Solutions (NASDAQ:BLFS) and LivaNova (NASDAQ:LIVN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, valuation and earnings.

Risk & Volatility

BioLife Solutions has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500. Comparatively, LivaNova has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500.

Earnings & Valuation

This table compares BioLife Solutions and LivaNova's top-line revenue, earnings per share and valuation.

BioLife Solutions has higher earnings, but lower revenue than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

67.7% of BioLife Solutions shares are owned by institutional investors. Comparatively, 89.1% of LivaNova shares are owned by institutional investors. 22.3% of BioLife Solutions shares are owned by company insiders. Comparatively, 0.5% of LivaNova shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares BioLife Solutions and LivaNova's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings for BioLife Solutions and LivaNova, as reported by MarketBeat.com.

BioLife Solutions currently has a consensus target price of $32.4444, indicating a potential downside of 17.49%. LivaNova has a consensus target price of $67.8571, indicating a potential downside of 12.84%. Given LivaNova's higher probable upside, analysts plainly believe LivaNova is more favorable than BioLife Solutions.

BioLife Solutions (NASDAQ:BLFS) and CONMED (NYSE:CNMD) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, valuation and earnings.

Profitability

This table compares BioLife Solutions and CONMED's net margins, return on equity and return on assets.

Risk & Volatility

BioLife Solutions has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500. Comparatively, CONMED has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for BioLife Solutions and CONMED, as reported by MarketBeat.com.

BioLife Solutions currently has a consensus target price of $32.4444, indicating a potential downside of 17.49%. CONMED has a consensus target price of $104.60, indicating a potential downside of 14.64%. Given CONMED's higher probable upside, analysts plainly believe CONMED is more favorable than BioLife Solutions.

Institutional and Insider Ownership

67.7% of BioLife Solutions shares are owned by institutional investors. 22.3% of BioLife Solutions shares are owned by company insiders. Comparatively, 5.4% of CONMED shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares BioLife Solutions and CONMED's top-line revenue, earnings per share and valuation.

CONMED has higher revenue and earnings than BioLife Solutions. CONMED is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Summary

BioLife Solutions beats CONMED on 7 of the 13 factors compared between the two stocks.

InMode (NASDAQ:INMD) and BioLife Solutions (NASDAQ:BLFS) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends and profitability.

Profitability

This table compares InMode and BioLife Solutions' net margins, return on equity and return on assets.

Volatility and Risk

InMode has a beta of 1.95, suggesting that its stock price is 95% more volatile than the S&P 500. Comparatively, BioLife Solutions has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for InMode and BioLife Solutions, as provided by MarketBeat.

InMode presently has a consensus target price of $71.50, indicating a potential upside of 4.32%. BioLife Solutions has a consensus target price of $32.4444, indicating a potential downside of 17.49%. Given InMode's stronger consensus rating and higher probable upside, equities analysts plainly believe InMode is more favorable than BioLife Solutions.

Institutional and Insider Ownership

35.7% of InMode shares are owned by institutional investors. Comparatively, 67.7% of BioLife Solutions shares are owned by institutional investors. 22.3% of BioLife Solutions shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares InMode and BioLife Solutions' top-line revenue, earnings per share (EPS) and valuation.

InMode has higher revenue and earnings than BioLife Solutions. InMode is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Summary

InMode beats BioLife Solutions on 10 of the 14 factors compared between the two stocks.

Outset Medical (NASDAQ:OM) and BioLife Solutions (NASDAQ:BLFS) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends and profitability.

Institutional and Insider Ownership

84.6% of Outset Medical shares are owned by institutional investors. Comparatively, 67.7% of BioLife Solutions shares are owned by institutional investors. 22.3% of BioLife Solutions shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Outset Medical and BioLife Solutions' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Outset Medical and BioLife Solutions, as provided by MarketBeat.

Outset Medical presently has a consensus target price of $55.00, indicating a potential upside of 11.40%. BioLife Solutions has a consensus target price of $32.4444, indicating a potential downside of 17.49%. Given Outset Medical's higher probable upside, equities analysts plainly believe Outset Medical is more favorable than BioLife Solutions.

Earnings and Valuation

This table compares Outset Medical and BioLife Solutions' top-line revenue, earnings per share (EPS) and valuation.

Outset Medical has higher earnings, but lower revenue than BioLife Solutions.

Summary

BioLife Solutions beats Outset Medical on 7 of the 9 factors compared between the two stocks.

TransMedics Group (NASDAQ:TMDX) and BioLife Solutions (NASDAQ:BLFS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings and profitability.

Analyst Ratings

This is a breakdown of recent ratings and price targets for TransMedics Group and BioLife Solutions, as provided by MarketBeat.com.

TransMedics Group presently has a consensus price target of $24.00, indicating a potential downside of 30.82%. BioLife Solutions has a consensus price target of $32.4444, indicating a potential downside of 17.49%. Given BioLife Solutions' stronger consensus rating and higher probable upside, analysts clearly believe BioLife Solutions is more favorable than TransMedics Group.

Earnings & Valuation

This table compares TransMedics Group and BioLife Solutions' top-line revenue, earnings per share and valuation.

BioLife Solutions has higher revenue and earnings than TransMedics Group. TransMedics Group is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

TransMedics Group has a beta of 2.16, suggesting that its share price is 116% more volatile than the S&P 500. Comparatively, BioLife Solutions has a beta of 1.55, suggesting that its share price is 55% more volatile than the S&P 500.

Institutional & Insider Ownership

76.7% of TransMedics Group shares are held by institutional investors. Comparatively, 67.7% of BioLife Solutions shares are held by institutional investors. 13.1% of TransMedics Group shares are held by insiders. Comparatively, 22.3% of BioLife Solutions shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares TransMedics Group and BioLife Solutions' net margins, return on equity and return on assets.

Summary

BioLife Solutions beats TransMedics Group on 11 of the 14 factors compared between the two stocks.

BioLife Solutions (NASDAQ:BLFS) and Natus Medical (NASDAQ:NTUS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for BioLife Solutions and Natus Medical, as provided by MarketBeat.

BioLife Solutions currently has a consensus price target of $32.4444, indicating a potential downside of 17.49%. Given BioLife Solutions' stronger consensus rating and higher possible upside, analysts plainly believe BioLife Solutions is more favorable than Natus Medical.

Earnings and Valuation

This table compares BioLife Solutions and Natus Medical's gross revenue, earnings per share and valuation.

BioLife Solutions has higher earnings, but lower revenue than Natus Medical. Natus Medical is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

BioLife Solutions has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500. Comparatively, Natus Medical has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500.

Institutional and Insider Ownership

67.7% of BioLife Solutions shares are held by institutional investors. Comparatively, 89.7% of Natus Medical shares are held by institutional investors. 22.3% of BioLife Solutions shares are held by insiders. Comparatively, 1.5% of Natus Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares BioLife Solutions and Natus Medical's net margins, return on equity and return on assets.

Summary

BioLife Solutions beats Natus Medical on 8 of the 14 factors compared between the two stocks.